Genetic variation at the CYP2C19 gene associated with metabolic syndrome susceptibility in a South Portuguese population: Results from the pilot study of the European Health Examination Survey in Portugal

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Gaio, Vânia ^a   Nunes, Baltazar ^a   Fernandes, Aida ^b   Mendonça, Francisco ^c   Horta Correia, Filomena ^c   Beleza, Álvaro ^b   Gil, Ana Paula ^a   Bourbon, Mafalda ^a   Vicente, Astrid ^a   Dias, Carlos Matias ^a   Barreto Da Silva, Marta ^a  

^a NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^b Laboratório de Saúde Pública Dra Laura Ayres   (Portugal)

^c Centro de Saúde de Faro   (Portugal)

Author keywords

Continuous MetS score; CYP2C19 gene; Genetic association study; Metabolic syndrome

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA2; CYTOCHROME P450 2C19; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NUCLEAR FACTOR Y; THIOPURINE METHYLTRANSFERASE; TRIACYLGLYCEROL;

ADULT; AGED; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHYSICAL EXAMINATION; PHYSICAL INACTIVITY; PILOT STUDY; PORTUGAL; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84896738596     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-23     Document Type: Article

References (44)

1. The metabolic syndrome. Eckel RH, Grundy SM, Zimmet PZ, Lancet 2005 365 9468 1415 1428 10.1016/S0140-6736(05)66378-7 15836891 (Pubitemid 40523737)
2. The Metabolic Syndrome. Cornier M-A, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH, Endocr Rev 2008 29 7 777 822 10.1210/er.2008-0024 18971485
3. Síndrome metabólica em Portugal: prevalência e implicações no risco cardiovascular-Resultados do Estudo VALSIM. Fiuza M, Cortez-Dias N, Martins S, Rev Port Cardiol 2008 27 12 1495 1529 19280993
4. Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K, Fruchart J, James W, Loria C, Smith S, Circ 2009 120 1640 1645 10.1161/CIRCULATIONAHA.109.192644
5. Sedentary behaviour, physical activity and a continuous metabolic syndrome risk score in adults. Wijndaele K, Duvigneaud N, Matton L, Duquet W, Delecluse C, Thomis M, Beunen G, Lefevre J, Philippaerts RM, Eur J Clin Nutr 2007 63 3 421 429 17971826
6. Common familial influences on clustering of metabolic syndrome traits with central obesity and insulin resistance: the Kiel obesity prevention study. Bosy-Westphal A, Onur S, Geisler C, Wolf A, Korth O, Pfeuffer M, Schrezenmeir J, Krawczak M, Muller MJ, Int J Obes 2006 31 5 784 790 (Pubitemid 46663818)
7. Genetic variants and the metabolic syndrome: a systematic review. Povel CM, Boer JMA, Reiling E, Feskens EJM, Obes Rev 2011 12 11 952 967 10.1111/j.1467-789X.2011.00907.x 21749608
8. Human genetic variation and its contribution to complex traits. Frazer KA, Murray SS, Schork NJ, Topol EJ, Nat Rev Genet 2009 10 4 241 251 19293820
9. A Bivariate Genome-Wide Approach to Metabolic Syndrome: STAMPEED Consortium. Kraja AT, Vaidya D, Pankow JS, Goodarzi MO, Assimes TL, Kullo IJ, Sovio U, Mathias RA, Sun YV, Franceschini N, Diabetes 2011 60 4 1329 1339 10.2337/db10-1011 21386085
10. Pathway analysis of seven common diseases assessed by genome-wide association. Torkamani A, Topol EJ, Schork NJ, Genomics 2008 92 265 272 10.1016/j.ygeno.2008.07.011 18722519
11. A continuous metabolic syndrome risk score: utility for epidemiological analyses. Wijndaele K, Beunen G, Duvigneaud N, Matton L, Duquet W, Thomis M, Lefevre J, Philippaerts R, Diabetes Care 2006 29 2329 (Pubitemid 44899880)
12. An overview of the European Health Examination Survey Pilot Joint Action. Kuulasmaa K, Tolonen H, Koponen P, Kilpeläinen K, Avdicová M, Broda G, Calleja N, Dias C, Gösswald A, Kubinova R, et al. Arch Public Health 2012 70 1 20 10.1186/0778-7367-70-20 22958511
13. Instituto Nacional de Saúde Doutor Ricardo Jorge, Inquérito de Saúde com Exame Físico: Relatório do estudo realizado em São Brás de Alportel Lisboa: INSA. Departamento de Epidemiologia. Departamento da Promoção de Saúde e Doenças Crónicas 2012 http://hdl.handle.net/10400.18/981
14. FEHES-Feasibility of a European Health Examination Survey. http://www.thl.fi/fehes/index.html
15. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Lahiri DK, Numberger JI, Nucleic Acids Research 1991 19 19 5444 10.1093/nar/19.19.5444 1681511
16. HardyWeinberg: Graphical tests for Hardy-Weinberg equilibrium. R package version 1.4.1. Graffelman J, 2012 http://CRAN.R-project.org/package= HardyWeinberg
17. Distribuição conjunta de determinantes de saúde relacionados com comportamentos na população portuguesa. Matias Dias C, Briz T, Observações-Boletim epidemiológico. Vol.1, N°1, Jul-set 2012 Lisboa: Instituto Nacional de Saúde Doutor Ricardo Jorge http://hdl.handle.net/10400.18/878
18. National Center for Biotechnology Information. http://www.ncbi.nlm.nih. gov/
19. Genetic risk profiling for prediction of type 2 diabetes. Mihaescu R, Meigs J, Sijbrands E, Janssens AC, PLoS Curr 2011 3 1208
20. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL, Nat Genet 2010 42 2 105 116 10.1038/ng.520 20081858
21. Angiotensin I-converting enzyme: genotype and disease associations. Crisan D, Carr J, J Mol Diagn 2000 2 3 105 115 10.1016/S1525-1578(10)60624-1 11229513
22. Identification of a common variant at the NOS1AP locus strongly associated to QT-interval duration. Eijgelsheim M, Aarnoudse ALHJ, Rivadeneira F, Kors JA, Witteman JCM, Hofman A, van Duijn CM, Uitterlinden AG, Stricker BHC, Hum Mol Genet 2009 18 2 347 357 18927126
23. A Polymorphism in the β1 Adrenergic Receptor Is Associated with Resting Heart Rate. Ranade K, Jorgenson E, Sheu WHH, Pei D, Hsiung CA, Chiang F-T, Chen Y-DI, Pratt R, Olshen RA, Curb D, et al. Am J Hum Genet 2002 70 4 935 942 10.1086/339621 11854867 (Pubitemid 34259309)
24. Genetics and cardiovascular system: influence of human genetic variants on vascular function. Dias R, Gowdak M, Pereira A, Genes Nutr 2011 6 1 55 62 10.1007/s12263-010-0193-7 21437030
25. Single Nucleotide Polymorphisms that influence lipid metabolism. Interaction with Dietary Factors. Corella D, Ordovas JM, Annu Rev of Nutr 2005 25 341 390 10.1146/annurev.nutr.25.050304.092656 (Pubitemid 41209006)
26. From monogenic to polygenic obesity: recent advances. Hinney A, Vogel CG, Hebebrand J, Eur Child Adolesc Psychiatr 2010 19 3 297 310 10.1007/s00787-010- 0096-6
27. TRP64ARG polymorphism of the β3-adrenergic receptor gene and obesity risk: effect modification by a sedentary lifestyle. Marti A, Corbalán MS, Martínez-Gonzalez MA, Martinez JA, Diabetes Obes Metab 2002 4 6 428 430 10.1046/j.1463-1326.2002.00227.x 12406043 (Pubitemid 35345458)
28. Obesity, Smoking, and Frontal Brain Dysfunction. Bauer L, Dick D, Bierut L, Bucholz K, Edenberg H, Kuperman S, Kramer J, Nurnberger J, O'Connor S, Rice J, et al. Am J Addict 2010 19 5 391 400 10.1111/j.1521-0391.2010.00069.x 20716301
29. The neuropeptide Y system: Pathophysiological and therapeutic implications in obesity and cancer. Zhang L, Bijker MS, Herzog H, Pharmacol Ther 2011 131 1 91 113 10.1016/j.pharmthera.2011.03.011 21439311
30. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Goldstein JA, Br J Clin Pharmacol 2001 52 4 349 355 10.1046/j.0306-5251.2001. 01499.x 11678778 (Pubitemid 32939439)
31. Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk. Božina N, Bradamante V, Lovrić M, Arch Ind Hyg Toxicol 2009 60 217
32. Genetic Polymorphism of CYP2C19 Gene in the Stanislas Cohort. A link with Inflammation. Bertrand-Thiébault C, Berrahmoune H, Thompson A, Marie B, Droesch S, Siest G, Foernzler D, Visvikis-Siest S, Ann Hum Genet 2008 72 2 178 183 10.1111/j.1469-1809.2007.00417.x 18205890 (Pubitemid 351228460)
33. Pharmacogenomics of Thiopurine S Methyltransferase: Clinical Applicability of Genetic Variants, Clinical Applications of Pharmacogenetics. Pavlovic S, Zukic B, Nikcevic G, Clinical Applications of Pharmacogenomics Rijeka: Tech, Sanoudou D, 2012 75 94
34. A comprehensive review of genetic association studies. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K, Genet Med 2002 4 2 45 61 10.1097/00125817-200203000-00002 11882781 (Pubitemid 44698579)
35. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomás M, Masiá R, Marrugat J, Brugada R, Elosua R, Heart 2012 98 2 100 108 10.1136/hrt.2011.227652 21693476
36. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Zordoky BNM, El-Kadi AOS, Pharmacol Ther 2010 125 3 446 463 10.1016/j.pharmthera.2009.12.002 20093140
37. Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. Giusti B, Gori AM, Marcucci R, Abbate R, Expert Opin Drug Metab Toxicol 2010 6 4 393 407 10.1517/17425251003598878 20163283
38. CYP2C19 allele nomenclature. http://www.imm.ki.se/CYPalleles/cyp2c19.htm
39. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J, Br J Clin Pharmacol 2010 69 222 230 10.1111/j.1365-2125.2009.03578.x 20233192
40. Functional Polymorphism in the Neuropeptide Y Gene Promoter (rs16147) Is Associated with Serum Leptin Levels and Waist-Hip Ratio in Women. Mutschler J, Abbruzzese E, Wiedemann K, von der Goltz C, Dinter C, Mobascher A, Thiele H, Diaz-Lacava A, Dahmen N, Gallinat J, et al. Ann Nutr Met 2013 62 4 271 276 10.1159/000346799
41. Increasing association between a neuropeptide Y promoter polymorphism and body mass index during the course of development. Hohmann S, Buchmann AF, Witt SH, Rietschel M, Jennen-Steinmetz C, Schmidt MH, Esser G, Banaschewski T, Laucht M, Pediatr Obes 2012 7 6 453 460 10.1111/j.2047-6310.2012.00069.x 22941950
42. Central nervous system control of food intake and body weight. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW, Nat 2006 443 7109 289 295 10.1038/nature05026 (Pubitemid 44435142)
43. The pharmacogenetic basis of individual variation in thiopurine metabolism. Blaker PA, Arenas-Hernandez M, Marinaki AM, Sanderson JD, Pers Med 2012 9 7 707 725 10.2217/pme.12.85
44. What is next after the genes for autoimmunity? Castiblanco J, Arcos-Burgos M, Anaya JM, BMC Med 2013 11 197 10.1186/1741-7015-11-197 24107170